Study into the effect of treatment with Verapamil on the number of insulin-producing cells in type 1 diabetes patients (Image-Ver-A-T1D)

Phase 1

• Conditions: Type 1 Diabetes; MedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: EUCTR2020-004966-20-AT
• Lead Sponsor: Radboud University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-07
• Last Update Posted: 9 May 2022

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

- Have given written informed consent
- Are aged between 18 and 45 years old
- Are included in the VER-A-T1D trial

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Treatment with synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors (to exclude interferences with imaging), specifically mentioned although in principle part of exclusion criteria VER-A-T1D.
•Renal disease defined as MDRD < 40 ml/min/1.73m2
•Pregnancy or the wish to become pregnant within 2 months after second PET/CT scan.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified